PHILADELPHIA, Oct. 31, 2007 (PRIME NEWSWIRE) -- Hemispherx Biopharma, Inc. (AMEX:HEB), today announced plans to present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference.
On Monday, November 5 at 12:00 noon Eastern Time, Hemispherx Biopharma is scheduled to present in the Spellman Room, 5th floor, The New York Palace Hotel in New York City. A replay of the presentation will be available on the Hemispherx website (www.hemispherx.net), following the live event, for a period of 90 days.
The presentation will expand on two features of the Company's platform technology which are featured in the current issues of pharmaceutical newsletters including BioWorld Today, BioCentury, Scrip, the Pink Sheet and New Scientist. Government researchers at the U. S. Centers for Disease Control (CDC) and the Japan's National Institutes of Infectious Diseases (JNIID) have independently identified major disease opportunities, with unmet medical needs, which may be addressed by the technology.
These opportunities are addressed in part in current issues of the Journal of Infectious Diseases (vol.198, p.1313, Oct. 2007) and the New Scientist (issue 2627, p. 5, Oct. 27,2007) which highlight avian influenza.
On October 10, 2007, the Company filed the first New Drug Application (NDA) for potential treatment of Chronic Fatigue Syndrome (CFS), another unmet medical need, with a lead drug candidate from the platform, poly I. poly C12U (Ampligen(r)), an investigational therapeutic.
About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an advanced biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection(r) (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics Ampligen(r) and Oragens(r). Ampligen(r) and Oragens(r) represent experimental RNA nucleic acids being developed for globally important debilitating diseases and disorders of the immune system. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has in excess of 100 patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection(r)). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products. For more information please visit www.hemispherx.net
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the Company (including Ampligen(r), Alferon LDO and Oragens) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon N Injection(r) do not imply that the product will ever be specifically approved commercially for these other treatment indications.